Diagnosis of Cardiac Amyloidosis: Clinical and Echocardiographic Features

  • Rekha Mankad
  • Martha Grogan
Echocardiography (F Asch and S Costa, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Echocardiography


Purpose of Review

This review is geared to address the various forms of amyloidosis which have cardiac involvement and discuss the echocardiographic findings that may be present in patients with cardiac amyloidosis.

Recent Findings

The use of echocardiography has revolutionized the diagnosis of cardiac amyloidosis. The diagnosis is often first suspected due to characteristic echocardiographic findings. Although no single finding is pathognomonic, there are a constellation of features that point to the diagnosis including increased left and right ventricular wall thickness, thickened cardiac valves and atrial walls, and a pericardial effusion. Alterations in diastolic function with evidence of elevated filling pressures are common. The use of myocardial strain imaging has allowed for earlier detection of cardiac amyloidosis and has revealed a distinctive pattern, sometimes suggesting the diagnosis when more classic findings are subtle or absent. Multiple echocardiographic findings have been found to be prognostic in cardiac amyloid. Using current techniques, functional measures such as myocardial strain and stroke volume index are more powerful predictors of outcome than myocardial thickness. While other imaging modalities are complementary including cardiac magnetic resonance imaging and nuclear medicine scintigraphy techniques using bone tracers, echocardiography remains a mainstay in the diagnosis and follow-up of patients with cardiac amyloidosis.


Echocardiography is a critical tool in the evaluation of the patient with heart failure, as well as those with unexplained chest pain and arrhythmias. Key findings on an echocardiogram can help alert the clinician to the presence of cardiac amyloidosis. The degree of cardiac dysfunction in a patient with systemic amyloidosis correlates with prognosis. Recognition of subtle echocardiographic findings may allow for earlier and more aggressive treatment to improve overall mortality in patients with cardiac amyloidosis.


Cardiac amyloidosis Diastolic dysfunction Light chain Transthyretin Global longitudinal strain Pyrophosphate 


Compliance with ethical standards

Conflict of Interest

Both authors declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol. 2015;24(6):343–50.CrossRefGoogle Scholar
  2. 2.
    • Grogan M, Dispenzieri A. Natural history and therapy of AL cardiac amyloidosis. Heart Fail Rev. 2015;20(2):155–62 Comprehensive review of light chain cardiac amyloidosis with focus on clinical and imaging findings as well as treatment options. CrossRefGoogle Scholar
  3. 3.
    Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66(21):2451–66.CrossRefGoogle Scholar
  4. 4.
    Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014–20.CrossRefGoogle Scholar
  5. 5.
    Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112(13):2047–60.CrossRefGoogle Scholar
  6. 6.
    Grogan M, Dispenzieri A, Gertz MA. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. Heart. 2017;103(14):1065–72.CrossRefGoogle Scholar
  7. 7.
    Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91(2):141–57.CrossRefGoogle Scholar
  8. 8.
    Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203–12.CrossRefGoogle Scholar
  9. 9.
    Cornwell GG III, Westermark P. Senile amyloidosis: a protean manifestation of the aging process. J Clin Pathol. 1980;33(12):1146–52.CrossRefGoogle Scholar
  10. 10.
    Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Failure. 2014;2(2):113–22.CrossRefGoogle Scholar
  11. 11.
    • Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–94 Discussion about the role of ATTRwt amyloidosis as an etiology for the diagnosis of heart failure with preserved ejection fraction (itself a complex clinical dilemma).CrossRefGoogle Scholar
  12. 12.
    • Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135(14):1357–77 Review of the approach to diagnosis cardiac amyloidosis particularly as it related to various presentations. CrossRefGoogle Scholar
  13. 13.
    Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–12.CrossRefGoogle Scholar
  14. 14.
    Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR III, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114(24):4957–9.CrossRefGoogle Scholar
  15. 15.
    Chamarthi B, Dubrey SW, Cha K, Skinner M, Falk RH. Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis. Am J Cardiol. 1997;80(9):1242–5.CrossRefGoogle Scholar
  16. 16.
    Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013;2(2):e000098.CrossRefGoogle Scholar
  17. 17.
    Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation. 2016;133(3):282–90.CrossRefGoogle Scholar
  18. 18.
    Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007;116(21):2420–6.CrossRefGoogle Scholar
  19. 19.
    Zubkov AY, Rabinstein AA, Dispenzieri A, Wijdicks EF. Primary systemic amyloidosis with ischemic stroke as a presenting complication. Neurology. 2007;69(11):1136–41.CrossRefGoogle Scholar
  20. 20.
    Falk RH, Alexander KM, Liao R, Dorbala S. AL (light-chain) cardiac amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol. 2016;68(12):1323–41.CrossRefGoogle Scholar
  21. 21.
    Siddiqi OK, Sanchorawala V, Ruberg FL. Echocardiography and survival in light chain cardiac amyloidosis: back to basics. Circ Cardiovasc Imaging. 2018;11(5):e007826.CrossRefGoogle Scholar
  22. 22.
    Mookadam F, Haley JH, Olson LJ, Cikes M, Mookadam M. Dynamic left ventricular outflow tract obstruction in senile cardiac amyloidosis. Eur J Echocardiogr. 2006;7(6):465–8.CrossRefGoogle Scholar
  23. 23.
    Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005;95(4):535–7.CrossRefGoogle Scholar
  24. 24.
    Suresh R, Grogan M, Maleszewski JJ, Pellikka PA, Hanna M, Dispenzieri A, et al. Advanced cardiac amyloidosis associated with normal interventricular septal thickness: an uncommon presentation of infiltrative cardiomyopathy. J Am Soc Echocardiogr. 2014;27(4):440–7.CrossRefGoogle Scholar
  25. 25.
    Fealey ME, Edwards WD, Buadi FK, Syed IS, Grogan M. Echocardiographic features of cardiac amyloidosis presenting as endomyocardial disease in a 54-year-old male. J Cardiol. 2009;54(1):162–6.CrossRefGoogle Scholar
  26. 26.
    Klein AL, Hatle LK, Taliercio CP, Oh JK, Kyle RA, Gertz MA, et al. Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation. 1991;83(3):808–16.CrossRefGoogle Scholar
  27. 27.
    • Castano A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38(38):2879–87 Paper illustrating two complex conditions which may occur in the elderly patient: severe aortic stenosis and cardiac amyloidosis. How the presence of cardiac amyloidosis may result in low flow, low gradient aortic stenosis.CrossRefGoogle Scholar
  28. 28.
    Cirulis MM, Emerson LL, Bull DA, Hatton N, Nativi-Nicolai J, Hildebrandt GC, et al. Pulmonary arterial hypertension in primary amyloidosis. Pulm Circ. 2016;6(2):244–8.CrossRefGoogle Scholar
  29. 29.
    Milani P, Dispenzieri A, Scott CG, Gertz MA, Perlini S, Mussinelli R, et al. Independent prognostic value of stroke volume index in patients with immunoglobulin light chain amyloidosis. Circ Cardiovasc Imaging. 2018;11(5):e006588.CrossRefGoogle Scholar
  30. 30.
    Bellavia D, Abraham TP, Pellikka PA, Al-Zahrani GB, Dispenzieri A, Oh JK, et al. Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography. J Am Soc Echocardiogr. 2007;20(10):1194–202.CrossRefGoogle Scholar
  31. 31.
    Porciani MC, Lilli A, Perfetto F, Cappelli F, Massimiliano Rao C, Del Pace S, et al. Tissue Doppler and strain imaging: a new tool for early detection of cardiac amyloidosis. Amyloid. 2009;16(2):63–70.CrossRefGoogle Scholar
  32. 32.
    Koyama J, Falk RH. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging. 2010;3(4):333–42.CrossRefGoogle Scholar
  33. 33.
    • Barros-Gomes S, Williams B, Nhola LF, Grogan M, Maalouf JF, Dispenzieri A, et al. Prognosis of light chain amyloidosis with preserved LVEF: added value of 2D speckle-tracking echocardiography to the current prognostic staging system. JACC Cardiovasc Imaging. 2017;10(4):398–407 Discussion about the utility of strain imaging, along with other markers of cardiac amyloidosis, for prognostic determination.CrossRefGoogle Scholar
  34. 34.
    Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 2014;129(18):1840–9.CrossRefGoogle Scholar
  35. 35.
    Boynton SJ, Geske JB, Dispenzieri A, Syed IS, Hanson TJ, Grogan M, et al. LGE provides incremental prognostic information over serum biomarkers in AL cardiac amyloidosis. JACC Cardiovasc Imaging. 2016;9(6):680–6.CrossRefGoogle Scholar
  36. 36.
    Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111(2):186–93.CrossRefGoogle Scholar
  37. 37.
    Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010;3(2):155–64.CrossRefGoogle Scholar
  38. 38.
    White JA, Kim HW, Shah D, Fine N, Kim KY, Wendell DC, et al. CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis. JACC Cardiovasc Imaging. 2014;7(2):143–56.CrossRefGoogle Scholar
  39. 39.
    Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013;6(4):488–97.CrossRefGoogle Scholar
  40. 40.
    Banypersad SM, Sado DM, Flett AS, Gibbs SD, Pinney JH, Maestrini V, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2013;6(1):34–9.CrossRefGoogle Scholar
  41. 41.
    Rapezzi C, Guidalotti P, Salvi F, Riva L, Perugini E. Usefulness of 99mTc-DPD scintigraphy in cardiac amyloidosis. J Am Coll Cardiol. 2008;51(15):1509–10 author reply 10.CrossRefGoogle Scholar
  42. 42.
    Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195–201.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Rekha Mankad
    • 1
  • Martha Grogan
    • 1
  1. 1.RochesterUSA

Personalised recommendations